de Boer Marieke T, Molenaar I Quintus, Porte Robert J
Department of Surgery, Section Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Dig Surg. 2007;24(4):259-64. doi: 10.1159/000103656. Epub 2007 Jul 27.
Partial liver resections are the treatment of choice for patients with a malignant liver or bile duct tumor. The most frequent indications for partial liver resections are colorectal metastasis, hepatocellular carcinoma (HCC) and cholangiocarcinoma. Liver resection is the only therapy with a chance for cure in these patients. Refinements in surgical technique and increasing experience have contributed to a reduction in perioperative morbidity and mortality in recent years. Despite these improvements, partial liver resections remain a major surgical procedure and carry the risk for excessive blood loss and a subsequent need for blood transfusion. Blood transfusions have been associated with systemic side effects, such as depression of the immune system. Several studies have suggested that perioperative blood loss or transfusions have a negative impact on postoperative outcome. However, it has been debated whether this is due to a real cause-effect relationship or merely the result of more complicated surgery. We have reviewed the literature concerning studies focusing on the relationship between blood loss and blood transfusion during liver surgery for malignant tumors and postoperative outcome. Most studies were based on a retrospective analysis of single center experiences, using uni- and multivariate statistical methods. Most studies have demonstrated a significant and clinically relevant association between blood transfusion and postoperative mortality and morbidity, especially postoperative infectious complications. The effect of blood transfusions on tumor recurrence and more long-term mortality is much less clear and evidence varies depending on the type of malignancy. The strongest indication that blood transfusion may have an impact on tumor recurrence has been found for patients with early stages of HCC. However, overall, no such effect could be demonstrated for patients undergoing partial liver resection for late stages of HCC, colorectal liver metastasis or cholangiocarcinoma.
肝部分切除术是治疗肝或胆管恶性肿瘤患者的首选方法。肝部分切除术最常见的适应证是结直肠癌肝转移、肝细胞癌(HCC)和胆管癌。肝切除术是这些患者唯一有可能治愈的治疗方法。近年来,手术技术的改进和经验的增加有助于降低围手术期的发病率和死亡率。尽管有这些改进,肝部分切除术仍然是一项 major surgical procedure,并且存在失血过多以及随后需要输血的风险。输血与全身副作用相关,如免疫系统抑制。多项研究表明,围手术期失血或输血对术后结局有负面影响。然而,这是由于真正的因果关系还是仅仅是更复杂手术的结果一直存在争议。我们回顾了有关研究的文献,这些研究聚焦于恶性肿瘤肝手术期间失血和输血与术后结局之间的关系。大多数研究基于对单中心经验的回顾性分析,采用单变量和多变量统计方法。大多数研究表明输血与术后死亡率和发病率之间存在显著且具有临床相关性的关联,尤其是术后感染并发症。输血对肿瘤复发和更长期死亡率的影响尚不清楚,证据因恶性肿瘤类型而异。对于早期HCC患者,发现输血可能对肿瘤复发有影响的最有力指征。然而,总体而言,对于因晚期HCC、结直肠癌肝转移或胆管癌接受肝部分切除术的患者,未发现这种影响。